Search
Lactic acid
go.drugbank.com/drugs/DB04398ApprovedInvestigationalVet approvedThe concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed) Sodium lactate is the sodium salt of lactic acid, and has a mild saline taste. … It is produced by fermentation of a sugar source, such as corn or beets, and then, by neutralizing the resulting lactic acid to create a compound having the formula NaC3H5O3.
Mixtures: CAPD/DPCA 2 Stay Safe Link Solution for Peritoneal Dialysis, CAPD/DPCA 3 Stay Safe Link Solution for Peritoneal DialysisMedium-chain triglycerides
go.drugbank.com/drugs/DB13959ApprovedInvestigationalMedium-chain triglycerides (MCTs) are triglycerides made up of a glycerol backbone and three fatty acids with an aliphatic tail of six to 12 carbon atoms.
Mixtures: OMEGA PLUS EMULSION FOR INFUSION, SmofKabiven Emulsion for InfusionCategories: Solutions for Parenteral NutritionRifamycin
go.drugbank.com/drugs/DB11753ApprovedInvestigationalWithdrawn[L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801] … Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium _Amycolatopsis mediterranei_, also known as _Streptomyces
Categories: Antibiotics for Topical Use, Antiinfectives for Systemic UseCasirivimab
go.drugbank.com/drugs/DB15941ApprovedInvestigationalThey are reserved for Emergency Use Authorization (EUA) only.[L23524] In November 2021, the same indication was approved by the EMA. … [L23539] This drug is a combination of antibodies derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered from COVID-19.
Categories: Antiinfectives for Systemic Use, Approved Treatments for COVID-19Nomifensine
go.drugbank.com/drugs/DB04821ApprovedWithdrawnApproval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets. … FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal Register of June 17, 1986 (51 FR 21981)).
Iopofosine I-131
go.drugbank.com/drugs/DB15244InvestigationalIopofosine I-131 (NM-404 I-131) is under investigation in clinical trial NCT01495663 (Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned).
Synonyms: 2-((HYDROXY((18-(4-(131I)IODOPHENYL)OCTADECYL)OXY)PHOSPHINYL)OXY)-N,N,NTRIMETHYLETHANAMINIUM INNER SALT, Ethanaminium, 2-((hydroxy((18-(4-(iodo-131I)phenyl)octadecyl)oxy)phosphinyl)oxy)-N,N,N-trimethyl-, inner saltRomidepsin
go.drugbank.com/drugs/DB06176ApprovedInvestigationalRomidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy
Categories: Bile Salt Export Pump InhibitorsMultiple Carboxylase Deficiency, Neonatal or Early Onset Form
smpdb.ca/view/SMP0000564DiseaseThe BTD gene encodes for biotinidase and the HLCS gene encodes for holocarboxylase synthetase. … Holocarboxylase synthetase deficiency also called Multiple Carboxylase Deficiency, Neonatal or Early Onset Form, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder of either mutations
Garetosmab
go.drugbank.com/drugs/DB16379ApprovedInvestigational[L63940] It is a fully human IgG4 monoclonal antibody that binds and neutralizes activin A, blocking activin A from activating the mutant ACVR1 receptor that, in FOP, drives the formation of heterotopic … [L63940] By preventing this aberrant signaling, it reduces the formation of new abnormal bone.[L63940] It is administered by intravenous infusion every four weeks.
Catumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnCatumaxumab was approved for market in Canada in May 2012 for the same condition [FDA Label]. It is currently available under the brand name Removab. … Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122].